EuroBioForum 2013 2nd Annual Conference 27-28 May 2013 - Hilton Munich City, Munich, Germany http://www.eurobioforum.eu/2013 ======================================= # KEYNOTE PRESENTATION # m4 -> P4 Dr Horst Domdey Managing Director at BioM (co-host of EuroBioForum 2nd Annual Conference 2013) ======================================= http://www.eurobioforum.eu

1. www.m4.de
m4 g P4
Horst Domdey
BioM

2. www.m4.de
Cluster
Management
for Munich
Hospitals
in Munich
Biotech
and Pharma
in Munich
Science
in Munich
Personalized Medicine in Munich
€ 100 M
Program
on
Personalized
Medicine

3. www.m4.de
In June 2012 Corimmun
was acquired by Jansen-Cilag
COR-1 is a cyclic peptide
which neutralizes
stimulatory autoimmune
antibodies directed against
the beta-adrenergic receptor
mimicking the effect of
natural ligands like
adrenaline and thus leading
to a chronic over-stimulation
of the receptor.
Consequently this leads to
hypertrophy and reduced
function of the heart.
• Ex vivo, COR-1 showed good
efficacy to neutralize anti ß1
receptor autoantibodies.
• In animal models, COR-1
prevented the generation of heart
failure and also reversed existing
heart failure.
• In a placebo-controlled phase
I clinical trial COR-1 was shown
to be well tolerated.
• COR-1 is now being investigated
in a phase II clinical trial; it is
administered to a subgroup of
heart failure patients who have
been stratified by a specific
diagnostic test.
COR-1 – an m4 Lighthouse Project

4. www.m4.de
m4 Scouting & Incubation
• m4 Scouting
Identification of (bio)pharmaceutical research
projects with a high innovationspotentia
• m4 Award
Regional pre-seed program for innovative
research projects in the field of biomarkers
and drug development
• m4 Mentor Circle
Professional mentoring by retired experts from
academia and industry
• m4 Incubation
Assisted incubation of the m4 Award projects

5. www.m4.de
Predictive
Biomarkers
- DNA/RNA-omics
- Proteomics
P4 Medicine – Healthcare of the Future
Personalized
Stratification of Patients
- Herceptin
- Erbitux
- . . .
Preventive
Life Style and Treatment
- Phenylketonuria
- Diabetes
- Cancer
Participatory
Informed Decisions
by informed Patients
- 1000$ Genome

6. www.m4.de
4 Challenges
1. Health Economics
2. Alternative individualized treatments
3. Biomarkers
4. IT